FibroBiologics gains on patent related to insulin-producing cell transplant technology
BUZZ-FibroBiologics gains on patent related to insulin-producing cell transplant technology ** Shares of biotech firm FibroBiologics FBLG.O rise 2% to $1.00 premarket
** Co says U.S. Patent Office granted patent covering use of fibroblasts to improve transplantation of insulin-producing islet cells for type 1 diabetes, an autoimmune disease where the body destroys insulin-producing cells
** Patent aims to improve survival and long-term function of transplanted islets, addressing a key hurdle in islet transplantation
** Co says technology could help more patients benefit from each donor pancreas by reducing loss of transplanted islets
** Says fibroblasts may improve blood vessel formation, reduce cell stress and support transplanted tissue survival
** Adds patent also has potential applications beyond diabetes in other cell and tissue transplantation procedures
** As of last close, stock down ~78% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts